Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19)
| Autor: | Fulden Ulucan, Anand Narayan Singh, Lakkakula V.K.S. Bhaskar, Henu Kumar Verma, Neha Merchant, Cansu İlke Kuru, Poonam Verma, Antaripa Bhattacharya, Manish Kumar Verma |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Scopus MEDLINE World Health Organization Article law.invention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Clinical trials Randomized controlled trial law Correspondence Corona pandemic Medicine media_common.cataloged_instance Humans European union Intensive care medicine lcsh:QH301-705.5 media_common Protocol (science) lcsh:R5-920 Clinical Trials as Topic business.industry SARS-CoV-2 Public health Vaccination COVID-19 General Medicine COVID-19 Drug Treatment Clinical trial Europe 030104 developmental biology lcsh:Biology (General) 030220 oncology & carcinogenesis Therapeutic lcsh:Medicine (General) business |
| Zdroj: | Biomedical Journal Biomedical Journal, Vol 43, Iss 5, Pp 424-433 (2020) |
| ISSN: | 2320-2890 |
| Popis: | Background Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. Methods MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic agents for human therapy in patients with COVID-19 up to May 2020. Results We have extracted data from 60 clinical trials. Amongst these trials, 34 were from the European Union database of clinical trials and 26 from the National Institute of health. The data selection procedure includes active, completion, and recruitment in progress status. Most of the clinical trials are ongoing and hence, there is a lack of precise results for the treatment. Conclusions There is a lack of high-quality clinical evidence. The protocol to be developed requires large randomized clinical trials with a combination of available drugs and prospective therapies. We propose the usage of a large number of cases and different statistical analyses to conduct systematic clinical trials. This could provide comprehensive information about the clinical trial and potential therapeutic progress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|